Sobetirome

Drug Profile

Sobetirome

Alternative Names: GC-1; QRX-431

Latest Information Update: 23 Jul 2013

Price : $50

At a glance

  • Originator University of California at San Francisco
  • Developer QuatRx Pharmaceuticals
  • Class Acetic acids; Antihyperlipidaemics; Benzhydryl compounds; Obesity therapies; Phenols; Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lipid metabolism disorders; Obesity

Most Recent Events

  • 31 Dec 2010 Discontinued - Phase-I for Lipid metabolism disorders in USA (PO)
  • 31 Dec 2010 Discontinued - Phase-I for Obesity in USA (PO)
  • 18 Jun 2008 Pharmacodynamics data from phase I trials in Lipid metabolism disorders presented at the 90th Annual Meeting of the Endocrine Society (ENDO-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top